UNASSIGNED: e15515 Background: @entity298 ( @entity298 ) has a poor prognosis with a median survival of 12-25 months. Unlike @entity43 , there is no published data on the effectiveness of @entity13198 ( @entity13198 ) in @entity298 and it is not routine practice. Our series aimed to compare outcomes in @entity1 with @entity298 treated with @entity13198 following chemotherapy compared with @entity1 treated with chemotherapy alone. METHODS: A retrospective case note analysis was undertaken of all @entity1 ' of two consultants in 4 hospitals in the West Midlands diagnosed with @entity298 between May 2000-Nov 2008 identified through medical records. Data was analysed for age, performance status, response to chemotherapy, surgical outcomes, subsequent treatments, site of relapse, median @entity1054 ( @entity1054 ), and median @entity1349 ( @entity1349 ). Analysis for @entity1054 and @entity1349 was undertaken using both Kaplan-Meier and log rank analysis. RESULTS: We identified 44 @entity1 with histologically proven @entity298 between May 2000-October 2008. 41 @entity1 received chemotherapy. 19 received @entity3003 alone, 20 @entity3003 - @entity1311 and 2 @entity3003 - @entity136 . 17/44 @entity1 (39%) went on for @entity13198 following chemotherapy and 15/17 had optimal debulking. 3/17 had a complete pathological response. To date 11/17(65%) @entity1 have recurred in the interval surgical group compared with 24/27(89%) in the non-interval surgery group. Median @entity1054 was 25m (range = 8-33m) vs. 9m (0-30m) p=0.0001. 14/17(82%) in the surgical group have reached 2-year survival vs. 10/27(37%) in the non-surgical group. Median @entity1349 was 48 months in the interval surgery group vs. 21 months in the non-surgical group, p=0.0006. The median @entity1349 for all @entity1 was 36 months. CONCLUSIONS: The median @entity1349 for all @entity1 was 36m which compares favourably with previously published survival data of 12-25 months. @entity13198 in selected cases of @entity298 seems to improve median @entity1349 and @entity1054 in @entity298 and should be considered in all @entity1 who have a good response to chemotherapy.

Outcomes following XXXX in primary peritoneal carcinoma.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['Paclitaxel'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine'] @entity13198 :: ('OMIM:610141', 'Disease') :: ['IDS', 'interval debulking surgery'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression'] @entity298 :: ('MESH:D010538', 'Disease') :: ['Primary peritoneal carcinoma', 'PPC'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity13198 :: (OMIM:610141,Disease) :: ['interval debulking surgery']
